Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Le (Biberach an der Riss, Germany), V. Schroeder (Biberach an der Riss, Germany), J. Schütt (Biberach an der Riss, Germany), J. Wirth (Biberach an der Riss, Germany), A. Campos (La Jolla, United States of America), J. Li (Ridgefield, United States of America), M. Thomas (Biberach an der Riss, Germany), F. Herrmann (Biberach an der Riss, Germany), J. Garnett (Biberach an der Riss, Germany). In vitro modelling of epithelia-fibroblast interactions in idiopathic pulmonary fibrosis. 590

Member's Comments

No comment yet.

Related content which might interest you: PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip Source: ERS Lung Science Conference 2021 Year: 2021 A novel chronic murine model of idiopathic pulmonary fibrosis Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 Combined idiopathic pulmonary fibrosis and emphysema: functional characterization Source: Eur Respir J 2004; 24: Suppl. 48, 283s Year: 2004 The genetic basis of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1717-1727 Year: 2015 A first step against idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 130-131 Year: 2011 The changing treatment landscape in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 65-68 Year: 2015 The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (1) 1700379; 10.1183/13993003.00379-2017 Year: 2017 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 48: 538-552 Year: 2016 Non-invasive evaluation in prediction of pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Gender differences in serial pulmonary function testing in idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 579s Year: 2007 Accelerated ageing in idiopathic pulmonary fibrosis and pulmonary hypertension Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 Analysis of pulmonary function in patients with idiopathic pulmonary fibrosis (IPF): how stable is stable IPF? Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015